The purpose of this study was to evaluate acute toxicity of craniospinal irradiation (CSI) using helical tomotherapy (HT) and compare its dose distribution with that of conventional linac-based plans. Twelve patients with various brain tumors were treated with HT-CSI. Median patient age was 14 years (range: 4-37 years). Median CSI dose was 30.6 Gy in 18 fractions (range: 23.4-40 Gy in 13-25 fractions). Toxicities were assessed according to the Common Terminology Criteria for Adverse Events version 4.0. Before CSI, 11 patients (92%) received neoadjuvant chemotherapy, so acute toxicity was evaluated by comparing patient status before and after CSI. HT-CSI plans were compared with linac-based CSI plans made using Pinnacle 3 planning system in 9 patients. All patients completed planned CSI without interruption. Grade 3 or higher toxicities were leukopenia seen in 11 patients (92%), anorexia in 6 (50%), anemia in 5 (42%), and thrombopenia in 5 (42%). Administration of granulocyte colony-stimulating factor, platelet transfusion and total parenteral nutrition were required in 8 (67%), 5 (42%) and 5 (42%) patients, respectively. HT plans were superior to linac-based plans in terms of homogeneity and conformality in planning target volume (PTV). For most organs at risk (OARs), volumes receiving more than 10 Gy (V10 Gy) or 20 Gy (V20 Gy) were lower in HT plans. However, HT plans significantly increased mean doses to the lung, kidneys and liver, and V5 Gy of 6 OARs including the lung. Despite intensive neoadjuvant chemotherapy, acute toxicity of HT-CSI was acceptable. HT provided better dose distribution in PTV than conventional linac. In most OARs, smaller volumes received >10-20 Gy in HT plans, although larger volumes received 5-10 Gy.
Introduction
Craniospinal irradiation (CSI) is indicated in patients with malignant central nervous system (CNS) tumors that possess a propensity to develop cerebrospinal fluid (CSF) dissemination. CSI is considered mandatory for medulloblastoma, primitive neuroectodermal tumor and atypical teratoid/rhabdoid tumor, and is occasionally used for CNS lymphoma and leukemia, ependymoma and germ cell tumors (1) (2) (3) (4) . CSI has been traditionally delivered by using a conventional linac, but a number of problems have been recognized, including the existence of gaps between radiation fields (because CSI cannot be treated in one field), poor dose distribution in planning target volume (PTV) and high doses to organs at risks (OARs). Poor dose distribution in PTV may increase the risk of treatment failure, and high radiation doses to OARs may cause acute and late toxicities. Various techniques have been elaborated to solve the problems (5) (6) . Recently, CSI using intensity-modulated radiation therapy (IMRT) (7-8) and proton therapy (9-10) have been developed for the purpose of improving dose distribution in PTV and reducing doses to OARs.
Helical tomotherapy (HT) is considered one of the sophisticated modalities for CSI (11) (12) (13) (14) (15) (16) (17) (18) , because continuous helical delivery of 6 MV photons without field gaps and IMRT technique are expected to improve dose distribution in PTV and OARs. Moreover, megavoltage computed tomography (MVCT) (19-21) equipped on HT is expected to improve the accuracy of patient positioning. In this study, we assessed the feasibility of HT for CSI by evaluating acute toxicity and compared dose distribution of HT plans with simulated linac-based plans.
Materials and Methods

Patients
Since 2005, 12 patients were treated with CSI using HT at Nagoya Daini Red Cross Hospital and Hokuto Hospital. Patient characteristics are summarized in Table I . Among them, 4 patients had germ cell tumors and 3 had medulloblastoma. Seven of the 12 patients (58%) had intracranial or spinal dissemination. There were 6 pediatric patients under 13 years of age and 6 adult patients. Before CSI, all but 1 patient were treated with neoadjuvant chemotherapy including 3 treated with intensive chemotherapy and autologous peripheral blood stem cell transplantation (auto-PBSCT) (1-2, 22).
Simulation and Contouring
Thermoplastic devices and vacuum cradles were used for immobilization of patients. Images of the craniospinal axis were acquired on CT simulators (HiSpeed NXi and Discovery ST, GE Healthcare, Milwaukee, WI, USA) utilizing 3-mm contiguous slices in the supine position under free but shallow breathing. For a patient with a sitting height of over 60 cm, 5-mm contiguous CT slices were used, because sizes of data sets became very large.
Clinical target volumes (CTVs) and organs at risks (OARs) were contoured on the CT images using the Pinnacle 3 treatment planning system (Philips Medical Systems, Madison, WI). CTV CSI was contoured along CSF space identified on magnetic resonance imaging (MRI) including intervertebral foramens (23). The whole CSF space was considered appropriate for CTV CSI , because tumor cells could float in CSF.
Recently, other investigators also considered all of CSF space as CTV (7, 8, 12, 15) . Simultaneous integrated boost (SIB) technique (24) was applied to prescribe higher doses per each fraction to the posterior fossa and tumor bed than doses to CTV CSI in 7 patients (58%); CTV P (for the posterior fossa) and CTV T (for tumor bed) were contoured. The planning target volume (PTV) was composed of CTV with various margins. For PTV CSI and PTV P , approximately 1-cm margins were included in all directions around CTV CSI and CTV P , respectively. Margins for PTV T were 1-2 cm depending on histology in all directions. For planning of HT, PTV CSI was divided into three segments to improve dose homogeneity of PTV CSI and dose coverage of the region just above the cribriform plate and orbit. First segment was a small region just above the cribriform plate and orbit, second segment was other cranial regions, and third was the spinal canal. OARs were the lung, heart, liver, kidneys, lens, salivary glands, thyroid gland, esophagus, stomach, and vertebral bodies. The planning OAR volume (PRV) of the lens included 1-cm margins. Figure 1 shows an example of contours of CTVs, PTVs and OARs. All contouring of PTVs and OARs and treatment planning of patients were performed by two well-experienced radiation oncologists (C. S. and K. O.) at their institutions; the contouring and planning policy and procedure were identical between them.
Clinical Treatment Planning for Tomotherapy
CT-simulation and contour data sets were transferred to the tomotherapy planning station via a DICOM-RT protocol. Details of the inverse planning algorithm used, the optimization method and several parameters associated with the optimization in the tomotherapy planning station have been described previously (14, 25) . At first, users define several parameters: prescription dose, pitch, field width, resolution of calculation grid, and modulation factor. HT plans were generated with a field width of 5 cm in 9 patients and 2.5 cm in 3, a mean pitch of 0.287 to 0.5 (median 0.4), a modulation factor of 1.8 to 3.0 (median 3.0), and an actual modulation factor of 1.377 to 2.527 (median 1.915). Maximum dose and dose-volume histogram (DVH) objectives were defined and regulated during optimization for PTVs and OARs with differential penalties to obtain uniform and adequate PTVs coverage with maximum OARs sparing.
Treatment of Patients
Three pediatric patients required sedation. Pretreatment MVCT scanning was performed around the cervical to upper thoracic vertebrae level (sometimes wider range) before each fraction. MVCT images were fused with the planning kilovoltage CT for accurate repositioning. Dose prescriptions of CSI are summarized in Table II . The radiation doses of CSI were 23.4 Gy to 40 Gy in 13 to 25 fractions, with a median of 30.6 Gy (in 18 fractions). SIB technique was applied to 7 patients during CSI. After CSI, 6 patients received additional boost radiation to the tumor bed with doses of 10 to 32.4 Gy in 5 to 12 fractions. SIB technique was applied to 4 patients for boost radiation. One patient with germ cell tumor received whole-ventricular radiation at first (17 to 20 Gy in 10 fractions using SIB). However, because serum alpha-fetoprotein levels increased during the treatment, CSI with 30.6 Gy in 18 fractions reducing the dose to the whole ventricle to approximately 18 Gy using SIB was performed subsequently. The mean treatment time for each fraction was 1-cm margins. The superior-inferior field gaps were designed to be 0.5-1 cm to avoid overlapping according to the classic method of CSI (26). For comparison, HT-based IMRT plans were newly made to produce uniform dose distributions in all PTVs (PTV ALL ) including PTV CSI , PTV P , and PTV T without SIB technique. For this purpose, the prescribed mean dose of PTV ALL was 30.6 Gy in all patients, and the mean dose of PTV ALL was made as uniform as possible between HT and linac-based plans for the same patient. Two linac-based plans with shifting field gaps were generated and assumed to deliver the same doses (15.3 Gy) and fraction numbers (9 fractions). Therefore, the sum of the mean doses and the average of other statistics on those two plans were evaluated as actual dose distributions of linac-based plans. Figure 2 shows an example of linac-based plans. Figure 3 shows an example of dose distributions of HT and linac-based plans in a patient.
The mean dose (D mean ) of PTV ALL , the dose delivered to n% of the PTV ALL volume (Dn), the volume of PTV ALL receiving n% of the prescribed dose (Vn), D mean of OARs (lung, heart, liver, kidneys, PRV of lens, salivary glands, thyroid gland, esophagus, stomach, and vertebral bodies), and the volume of OARs receiving n Gy (Vn Gy) were calculated on both plans and compared. Differences in these parameters were examined by paired Student's t-test.
Results
Acute Toxicity Figure 4 shows changes of the grade of major acute toxicities before and after CSI. All 12 patients completed CSI without 790 seconds (range 497.3-979.7 s). The mean couch movement for each fraction was 72 cm (range: 54.2-86.1 cm). The mean total monitor unit (MU) for each fraction was 11330 MU (range: 7194 -14026 MU).
Acute Toxicity and Outcome
Acute toxicities were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Since most patients had received neoadjuvant treatment, acute toxicity was assessed by comparing patient symptoms and laboratory data before and after CSI. After CSI, 8 patients (67%) received adjuvant chemotherapy. So, we evaluated acute toxicities until starting adjuvant chemotherapy in these cases. In the remaining 4 patients, we evaluated acute toxicities occurring within 90 days after CSI. Survival and failure-free survival rates of the patients were calculated from the date of starting radiation therapy by the Kaplan-Meier method.
Comparison of Treatment Planning for Linac-based CSI and Tomotherapy
Conventional treatment plans using 6-MV X rays of a linac with a maximal collimator jaw length of 40 cm were made using the Pinnacle 3 system in 9 patients treated at Nagoya Daini Red Cross Hospital. Lateral opposed fields were used for the brain and cervical cord with 1-cm margins with the lens blocked. Depending on the height of patients, one or two posterior fields were used for the rest of the spinal cord. The lateral and inferior limits of posterior fields were designed to cover both PTV CSI and the vertebral bodies with Administration of granulocyte colony-stimulating factor (G-CSF), platelet transfusion, total parenteral nutrition and erythrocyte transfusion were necessary in 8 (67%), 5 (42%), 5 (42%), and 4 (33%) patients, respectively. Adjuvant chemotherapy was delayed for a month or longer in 2 patients (17%) because of delay in recovery from leukopenia.
Patient Outcome
The median follow-up period for living patients was 9 months (range, 4-51). Four patients (33%) relapsed; 2 had CSF dissemination, 1 had local recurrence and 1 had both. Two patients with AT/RT and 1 each with mixed germ cell interruption. Grade 3 or higher acute toxicities were leukopenia seen in 11 patients (92%), anorexia in 6 (50%), anemia and thrombopenia in 5 (42%) each, and fatigue in 1 (8%). Grade 2 or higher acute toxicities were leukopenia in all 12 patients, anemia in 10 (83%), thrombopenia and anorexia in 9 (75%) each, alopecia in 7 (58%), fatigue in 2 (17%), and esophagitis and diarrhea in 1 (8%) each. No patients developed >Grade 2 radiation pneumonitis. No correlations were found between total radiation doses of CSI and increases in grade of each toxicity during CSI by Spearman's rank correlation test. No differences in increases of grade for each toxicity were found by the use of SIB or boost irradiation (Mann-Whitney's U test). studies were planning studies; only a few patients have been treated actually. In the present study, we investigated both clinical outcome and dose distribution of HT-CSI. In our study, all but 1 patient had been treated with induction chemotherapy prior to CSI. Some investigators reported that chemotherapy given before CSI was associated with increased incidence of Grade 3 or 4 leukopenia and thrombopenia (27) (28) . Others also reported that patients treated with intensive chemotherapy and auto-PBSCT tended to develop hematological toxicities (22, 29) . In our study too, all 4 patients treated with intensive chemotherapy and auto-PBSCT developed Grade 3 or 4 hematological toxicities. Others, except for 1 patient, also received neoadjuvant chemotherapy, so that hematological toxicity was frequent in our study. Total radiation doses of CSI, as well as the use of SIB technique or additional boost radiation, did not influence the incidence and grade of acute toxicities. This may be due to the small number of patients. Anyhow, it seemed always necessary to pay attention to hematological toxicities especially in patients treated with induction chemotherapy. However, all completed planned CSI without treatment interruption. This may be possibly owing to the use of HT. Despite generally dismal outcome of the diseases treated and the presence of CSF dissemination at diagnosis in 7 patients, prognosis after HT of the 12 patients appeared to be at least as or possibly better than expected.
Almost all previous studies have reported superiority of HT plans over conventional linac-based plans. However, some of them only compared virtual simulation of HT plan with that of conventional CSI, and in these plans, they used narrower tumor and medulloblastoma relapsed. All of the 4 patients with relapse died of the disease. One patient with medulloblastoma had widespread CSF dissemination before HT; she was successfully treated and is alive without recurrence at 51 months after HT. Figure 5 and Table III show dose-volume indices of HT-based IMRT and linac-based plans for PTV ALL and OARs. All statistics associated with dose distribution of PTV ALL were better in the HT plan than in the linac plan. Except for the thyroid gland, esophagus and vertebral bodies, V5Gy (volumes receiving >5 Gy) of OARs was larger in the HT plan. On the other hand, D mean , V10Gy and V20Gy of the heart, salivary glands, thyroid gland, and esophagus were superior in the HT plan. For the lung and kidneys, V20 Gy (and V15 Gy too for the lung) were significantly smaller in the HT plan, but the HT plan was inferior to the linac plan regarding D mean and V5 Gy. For the liver, V10 Gy and V20 Gy were smaller in the HT plan, but D mean and V5 Gy were larger. For PRV of the lens, all data did not differ between the two plans. For the stomach, both V10 Gy and V20 Gy were smaller in the HT plan, although V5 Gy was larger and D mean was not significantly different. For vertebral bodies, D mean and V20 Gy were better in the HT plan.
Comparison of Mean Dose-volume Statistics between HT and Linac
Discussion
Possibility and feasibility of using HT for CSI have been reported by several groups (11-16), but many of the previous plans, and clarified the advantages and disadvantages of HT over linac. Using virtual HT plans, Sharma et al. (15) carried out similar comparison; their dose distribution in the lung was similar to ours, but the mean doses of HT to the kidney and liver were lower than ours. Such discrepancy can result from differences in HT planning including CTV contouring and size of PTV margins. As a problem of CSI plans in HT, inadequate dose coverage of the region just above the cribriform plate and orbit was reported (11). Therefore, we divided PTV into three segments and one of the segments was localized in the region just above the cribriform plate and orbit. Then, the dose of the segment was carefully monitored on DVH and determined. We believe that the method should improve dose coverage of this region satisfactorily.
Dose distributions of PTV and most OARs in the HT plans generally appeared to be better than those in the linac-based plans except for the lung, kidney, liver, PRV of lens, and stomach. Although V5 Gy was larger in the HT plans than in the linac-based plans in 6 OARs, V10-20 Gy seems to be more important than V5 Gy because the dose of 5 Gy is below the threshold for developing late toxicities in the OARs. Especially, late toxicities of CSI on the heart and thyroid gland from CSI were reported (30), and radiation-induced xerostomia was reported to have developed by relatively low radiation doses to salivary glands (31). Therefore, it seems meaningful to reduce doses to the heart, thyroid gland and salivary glands by HT. Some investigators previously reported sex-dependent gonadotoxicity was an important late toxicity of CSI (30); therefore we expect to avoid gonadotoxicity by reducing doses to the ovaries using HT (5, 8) .
Many investigators reported that lung toxicity was associated with the mean lung dose and the volume receiving lower doses (32) (33) (34) (35) . Therefore, important problems in HT-based IMRT plan appeared to be higher D mean in the lung and larger lung volume receiving lower doses. Penagaricano et al. (13) reported the anxiety associated with large volumes of the lung receiving low radiation doses but lack of acute radiation pneumonitis in clinical cases. Similarly, we experienced no Grade 2 or higher radiation pneumonitis. The mean lung dose and the volume receiving lower dose in our HT plans fully satisfied most thresholds of acceptable lung doses previously reported (32-33). However, a few investigators recommended relatively low V5 Gy thresholds, similar to our level in the HT plan, to avoid severe radiation pneumonitis (34) (35) . Acceptable levels of V5 Gy thus need to be determined in future studies, but at present, attentions should be paid to reduce lung V5 Gy. Among all OARs, the lung may be the most important in CSI using HT.
The dose-volume indices in the kidneys, liver, stomach and PRV of the lens were similar and were considered acceptable in both plans. However, it seems that doses to vertebral jaw widths and more strict constraints for OARs so that the times required for treatment became unrealistically long (11, 15) . In the present study, we compared HT plans that were similar to actually used ones with virtual linac-based bodies could not be lowered sufficiently. Late radiation toxicities of vertebral bodies include spinal growth impairment, scoliosis, and osteopenia (30, 36) . Spinal growth impairment is supposed to correlate with radiation doses of vertebral bodies, especially with approximate doses applied to CSI (30, 36) . IMRT seems to be able to reduce doses of vertebral bodies. However, dose heterogeneity in vertebral bodies possibly causes backward curvature and exacerbates scoliosis (8). Moreover, if it was tried to reduce doses of vertebral bodies, doses to other more important OARs (e.g. lung and kidneys) tended to increase. Therefore, we consider that dose homogeneity in vertebral bodies is more important than dose reduction for pediatric patients.
Although not yet readily available, proton therapy also appears to be one of the best techniques for CSI in respect of dose distributions of OARs (9, 10). Comparison between HT and proton therapy with respect to dose distribution, feasibility and toxicity should be a topic to be investigated in the near future.
Another important issue in HT-based IMRT is a concern about second malignancies. It was suggested that HT might increase the possibility owing to larger volumes of normal tissues exposed to lower radiation doses (7). However, HT was considerably effective in reducing volumes of normal tissues receiving higher radiation doses. Since the probability of second malignancies increases with dose, causal relationship between HT and increased second malignancies seems to remain unclear.
Conclusion
CSI using HT was feasible in pediatric as well as adult patients, and yielded promising outcome. Hematological toxicities were severest acute toxicities of CSI using HT, since all but 1 patient had received induction chemotherapy. Dose distributions in PTV and most OARs were better in HT-based IMRT plans than those in linac-based plan. Currently, HT appears to be the best modality for X-ray treatment of the craniospinal axis.
